Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial

Autor: Xingwang Li, Qingshan Zheng, Qingquan Liu, Jingyi Liang, Yuanlin Song, Ke Hu, Zifeng Yang, Lianguo Ruan, Boli Zhang, Lanjuan Li, Ying Bi, Zhen-Hua Jia, Wei Zhang, Nanshan Zhong, Mingfeng Han, Wei-jie Guan, Chaomin Wu, Yunting Zhang, Zhongping Duan
Rok vydání: 2021
Předmět:
PPS
per protocol set
HR
hazards ratio
medicine.medical_specialty
food.ingredient
Coronavirus disease 2019 (COVID-19)
FAS
full-analysis set
PV
protocol deviation
Pharmaceutical Science
LH
Lianhuaqingwen
MERS
Middle East Respiratory Syndrome coronavirus
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
Article
law.invention
03 medical and health sciences
0302 clinical medicine
food
Randomized controlled trial
law
Internal medicine
Drug Discovery
Clinical endpoint
medicine
symptom recovery
Prospective cohort study
Adverse effect
030304 developmental biology
Pharmacology
Covid-19
coronavirus disease 2019
0303 health sciences
Coronavirus disease 2019
business.industry
Outbreak
Capsule
conversion rate
CT
computed tomography
Complementary and alternative medicine
Lianhuaqingwen Capsule
030220 oncology & carcinogenesis
Herb
Molecular Medicine
95%CI
95% confidence interval
business
Zdroj: Phytomedicine
ISSN: 0944-7113
DOI: 10.1016/j.phymed.2020.153242
Popis: Background Coronavirus disease 2019 (Covid-19) has resulted in a global outbreak. Few existing targeted medications are available. Lianhuaqingwen (LH) capsule, a repurposed marketed Chinese herb product, has been proven effective for influenza. Purpose To determine the safety and efficacy of LH capsule in patients with Covid-19. Methods We did a prospective multicenter open-label randomized controlled trial on LH capsule in confirmed cases with Covid-19. Patients were randomized to receive usual treatment alone or in combination with LH capsules (4 capsules, thrice daily) for 14 days. The primary endpoint was the rate of symptom (fever, fatigue, coughing) recovery. Results We included 284 patients (142 each in treatment and control group) in the full-analysis set. The recovery rate was significantly higher in treatment group as compared with control group (91.5% vs. 82.4%, P=0.022). The median time to symptom recovery was markedly shorter in treatment group (median: 7 vs. 10 days, P0.05). No serious adverse events were reported. Conclusion In light of the safety and effectiveness profiles, LH capsules could be considered to ameliorate clinical symptoms of Covid-19.
Databáze: OpenAIRE
Externí odkaz: